Author

A. T. Reid

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Assay:proteomics· 1

Frequent Co-Authors

P. C. Veerati· 3 shared P. S. Pathinayake· 3 shared K. S. Nichol· 2 shared P. A. Wark· 2 shared P. M. Hansbro· 2 shared A. C.-Y. Hsu· 1 shared A. Singanayagam· 1 shared C. L. Grainge· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

P. C. Veerati

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Comparison of commercially available differentiation media on morphology, function, and virus-host interaction in conditionally reprogrammed human bronchial epithelial cells

N. T. Awatade, A. T. Reid, K. S. Nichol, K. F. Budden, P. C. Veerati, P. S. Pathinayake, C. L. Grainge, P. M. Hansbro, P. A. Wark

This study compares two differentiation media for conditionally reprogrammed human bronchial epithelial cells, finding structural and functional differences but no impact on viral infection outcomes.

bioRxiv · Apr 12, 2023 · PreprintCell Biology

SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro

A. C.-Y. Hsu, G. Wang, A. T. Reid, P. C. Veerati, P. S. Pathinayake, K. Daly, J. R. Mayall, P. M. Hansbro, J. C. Horvat, F. Wang, P. A. Wark

This study shows that SARS-CoV-2 spike protein induces inflammation and epithelial damage, which can be reduced by an antagonistic peptide and FDA-approved drugs.

bioRxiv · Sep 30, 2020 · PreprintImmunology

Anti-microbial immunity is impaired in COPD patients with frequent exacerbations

A. Singanayagam, S.-L. Loo, M. Calderazzo, L. J. Finney, M.-B. Trujillo-Torralbo, E. Bakhsoliani, J. L. Girkin, P. C. Veerati, P. S. Pathinayake, K. S. Nichol, A. T. Reid, J. Footitt, S. L. Johnston, N. Bartlett, P. Mallia

This study identifies impaired anti-viral and anti-microbial immunity in COPD patients with frequent exacerbations, linking reduced interferon and MBL-2 levels to increased bacterial loads and susceptibility to exacerbations.

bioRxiv · May 9, 2019 · PreprintImmunology